0000910267 false 0000910267 2022-06-01 2022-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): June 1, 2022

 

Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

001-13341 94-3171940
(Commission File Number) (IRS Employer Identification No.)

 

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080

(Address of principal executive offices and zip code)

 

650-244-4990

(Registrant's telephone number including area code)

 

(Registrant's former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.001 par value   TTNP   Nasdaq Capital Market

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

   

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

The information set forth in the second paragraph of Item 8.01 is incorporated by reference herein.

 

Item 8.01. Other Events.

 

On June 1, 2022, Titan Pharmaceuticals, Inc. (the “Company”) implemented a plan to reduce expenses and conserve capital that included a company-wide reduction in salaries and a scale back of certain operating expenses. The cost-savings measures are being undertaken to enable the Company to maintain sufficient resources as it works with its advisors on potential strategic alternatives for maximizing shareholder value.

 

As part of the aforementioned plan, Marc Rubin, Executive Chairman, and Kate Beebe DeVarney, President and Chief Operating Officer, agreed to waive 40% of their base salaries for the next six months.

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 2, 2022 TITAN PHARMACEUTICALS, INC.
   
  By: /s/ Kate Beebe DeVarney
    Name: Kate Beebe DeVarney, Ph.D.
    Title: Chief Operating Officer and President

 

3

 

Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Apr 2023 to May 2023 Click Here for more Titan Pharmaceuticals Charts.
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From May 2022 to May 2023 Click Here for more Titan Pharmaceuticals Charts.